Six business lessons from the Daiichi–Ranbaxy deal fiasco
In 2008, Daiichi had bought the Singh brothers' 34.82% stake for $2.4 billion in a deal valued at $4.6 billion. And then, the US FDA scrutiny happened
The Daiichi–Ranbaxy deal has once again grabbed headlines. Malvinder and Shivinder Mohan Singh, the former owners of Ranbaxy Laboratories Ltd, were ordered by a Singapore arbitration tribunal to pay $385 million to Japanese pharma company Daiichi Sankyo Co. Ltd, which had bought the firm in 2008. Daiichi has accused the brothers of misrepresenting the problems facing Ranbaxy when it acquired the firm.